WhiteOak Capital Mid Cap Fund
The Scheme is to seek to generate capital appreciation by actively investing in and managing a diversified portfolio primarily composed of mid-cap stocks.
Growthvine rating: 4/5 — ranked #4 of 33 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹22.38 (as of 2026-08-21) |
|---|
| AUM | ₹6,933 Cr |
|---|
| Expense ratio | 1.55% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Piyush Baranwal |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Sharpe ratio | 0.91 |
|---|
| Standard deviation | 16.87% |
|---|
| Max drawdown | -19.68% |
|---|
| Alpha | 4.07 |
|---|
| Beta | 0.91 |
|---|
Over 5 years, captured 100.7% of NIFTY Midcap 150's upside and 89.0% of its downside.
Market cap allocation
| Large cap | 6.1% |
|---|
| Mid cap | 71.7% |
|---|
| Small cap | 22.2% |
|---|
Concentration
| Top 5 holdings | 13.7% |
|---|
| Top 10 holdings | 24.0% |
|---|
| Total holdings | 133 |
|---|
| Index overlap | 39.0% |
|---|
| Active share | 61.0% |
|---|
Top holdings
- Clearing Corporation of India Ltd — 5.5%
- Max Financial Services Limited — 3.1%
- Bharti Hexacom Limited — 2.9%
- Federal Bank Ltd. — 2.8%
- Laurus Labs Limited — 2.5%
- COFORGE LIMITED — 2.4%
- Fortis Healthcare Ltd — 2.3%
- PB Fintech Limited — 2.2%
- The Phoenix Mills Ltd. — 2.1%
- Vishal Mega Mart Limited — 1.9%
Top sectors
- Banking & Financial — 12.1%
- Retail — 11.1%
- Pharma & Biotech — 9.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 11.6% | Q1 (Top) | #4 of 31 |
| 2025 | 5.2% | Q1 (Top) | #6 of 29 |
| 2024 | 33.4% | Q1 (Top) | #7 of 29 |
| 2023 | 41.5% | Q1 (Top) | #6 of 28 |